FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML

Allogeneic HCT has been increasingly used in the setting of FLT3 mutated AML. However, its role in conferring durable relapse-free intervals remains in question. Herein, we sought to investigate FLT3 mutational status on transplant outcomes. We conducted a retrospective cohort study of 262 consecuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yeohan, Magenau, John, Li, Yumeng, Braun, Thomas, Chang, Lawrence, Bixby, Dale, Hanauer, David A., Chughtai, Komal A., Gatza, Erin, Couriel, Daniel, Goldstein, Steven, Pawarode, Attaphol, Reddy, Pavan, Riwes, Mary, Connelly, James, Harris, Andrew, Kitko, Carrie, Levine, John, Yanik, Greg, Parkin, Brian, Choi, Sung Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720584/
https://www.ncbi.nlm.nih.gov/pubmed/26191952
http://dx.doi.org/10.1038/bmt.2015.170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720584/
https://www.ncbi.nlm.nih.gov/pubmed/26191952
http://dx.doi.org/10.1038/bmt.2015.170

Ejemplares similares